Literature DB >> 16378077

Mixed lymphocyte cultures can predict TCR Vbeta repertoires of T cells infiltrating kidney transplants during acute rejection episodes.

Marius T Paraoan1, Ali Bakran, Abdul Hammad, Robert A Sells, Stephen E Christmas.   

Abstract

Alloreactive T cell populations can show skewing of T-cell antigen receptor (TCR) Vbeta gene usage. The aims of the experiments were to compare in vivo and in vitro T cell alloresponses against donor alloantigens for TCR Vbeta gene usage. T-cell cultures from renal biopsies taken during acute rejection and pretransplant mixed lymphocyte cultures (MLC) were established from five renal transplant patients. TCR Vbeta gene usage, assessed with Vbeta family specific antibodies, showed that up to five different Vbeta families were significantly expanded. In four of five cases, there was close concordance between Vbeta families expanded from the biopsy and in MLC. T-cell clones from one renal biopsy were specific for the mismatched donor alloantigen and showed similar TCR Vbeta gene usage to the original T-cell line. The results show very similar patterns of TCR Vbeta gene usage in alloreactive T cells generated ex vivo or in vitro.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16378077     DOI: 10.1097/01.tp.0000181194.42642.97

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  2 in total

1.  Clonal CD8+ T Cell Persistence and Variable Gene Usage Bias in a Human Transplanted Hand.

Authors:  Joseph Y Kim; Arumugam Balamurugan; Kodi Azari; Christian Hofmann; Hwee L Ng; Elaine F Reed; Suzanne McDiarmid; Otto O Yang
Journal:  PLoS One       Date:  2015-08-19       Impact factor: 3.240

2.  Longitudinal Analysis of the T-cell Receptor Repertoire in Graft-infiltrating Lymphocytes Following Hand Transplantation.

Authors:  Joseph Y Kim; Zhengdeng Lei; Mark Maienschein-Cline; George E Chlipala; Arumugam Balamurugan; Sue V McDiarmid; Kodi Azari; Otto O Yang
Journal:  Transplantation       Date:  2021-07-01       Impact factor: 5.385

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.